---
title: "Co-Diagnostics (CODX) news: convertible notes"
url: "https://aibio.space/companies/diagnostics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "CODX convertible notes news: Co-Diagnostics issues senior secured convertible note to J.J. Astor. Co-Diagnostics, Inc. (NASDAQ: CODX), United States."
---

CODX Co-Diagnostics, Inc. NASDAQ · United States

# Co-Diagnostics (CODX) news CODX convertible notes news

Debt Financing · 2026-10-09

## [Co-Diagnostics issues senior secured convertible note to J.J. Astor](https://aibio.space/news/co-diagnostics-issues-senior-secured-convertible-note-j-j-astor/)

The note has an original principal amount of $2,835,000, repaid in weekly installments of $94,500. The final maturity date is May 7, 2027.

## Latest Co-Diagnostics news

1. 2026-10-09 Debt Financing [Co-Diagnostics takes up to $3.1 million in secured convertible loans](https://aibio.space/news/co-diagnostics-takes-up-3-1-million-secured-convertible-loans/) J.J. Astor & Co. is the lender. The initial note carries a $2.835 million principal amount, and the company says the proceeds will fund working capital.
2. 2026-09-16 Company Updates [Co-Diagnostics and ReadyGo to evaluate blood testing for Ebola](https://aibio.space/news/co-diagnostics-readygo-evaluate-blood-testing-ebola/) The companies will test whether ReadyGo's sample-preparation technology can work with the Co-Dx PCR platform on blood samples. Compatibility has not yet been established.
3. 2026-08-13 Company Updates [Co-Diagnostics reports second quarter 2026 results and flu and RSV test submission](https://aibio.space/news/co-diagnostics-reports-second-quarter-2026-results-flu-rsv-test/) The net loss was $6.3 million, or $1.46 per share, and cash and cash equivalents were $3.6 million at June 30, 2026. The company said it submitted a 510(k) for its flu A/B and RSV test.
4. 2026-07-31 Financings [Co-Diagnostics warrant inducement expected to raise about $2.67 million](https://aibio.space/news/co-diagnostics-warrant-inducement-expected-raise-about-2-67-million/) Holders of existing warrants agreed to exercise at $1.571 per share in exchange for new warrants at $1.56. Maxim Group LLC is the exclusive placement agent.
5. 2026-05-14 Company Updates [Co-Diagnostics reports first quarter 2026 results and $8.2 million in cash](https://aibio.space/news/co-diagnostics-reports-first-quarter-2026-results-8-2-million-cash/) The net loss was $9.1 million, or $4.06 per share, and cash and cash equivalents were $8.2 million at March 31, 2026. The company said enrollment in its upper respiratory test studies is complete.

## Co-Diagnostics at a glance

- **Ticker**: CODX

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $3.6 million

### Related companies

- [PACIFIC BIOSCIENCES OF CALIFORNIA, INC.](https://aibio.space/companies/pacific-biosciences-of-california/) NASDAQ: PACB
- [SHOULDER INNOVATIONS, INC.](https://aibio.space/companies/shoulder-innovations/) NYSE: SI
- [Brainsway](https://aibio.space/companies/brainsway/) NASDAQ: BWAY
- [Standard Dental Labs](https://aibio.space/companies/standard-dental-labs/) OTC: TUTH
- [Virax Biolabs Group](https://aibio.space/companies/virax-biolabs/) NASDAQ: VRAX
- [DarioHealth](https://aibio.space/companies/dariohealth/) NASDAQ: DRIO
- [COOPER COMPANIES, INC.](https://aibio.space/companies/cooper-companies/) NASDAQ: COO
- [CollPlant Biotechnologies](https://aibio.space/companies/collplant-biotechnologies/) NASDAQ: CLGN

### Also on NASDAQ

- [PRF Technologies](https://aibio.space/companies/prf-technologies/) PRFX
- [Jasper Therapeutics](https://aibio.space/companies/jasper-therapeutics/) JSPR
- [INTUITIVE SURGICAL INC](https://aibio.space/companies/intuitive-surgical/) ISRG
- [Grace Therapeutics](https://aibio.space/companies/grace-therapeutics/) GRCE
- [Coherus Oncology](https://aibio.space/companies/coherus-oncology/) CHRS
- [Kazia Therapeutics](https://aibio.space/companies/kazia-therapeutics/) KZIA

## Co-Diagnostics annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$622,489](https://www.sec.gov/Archives/edgar/data/1692415/000149315226014158/) | [$3.9 million](https://www.sec.gov/Archives/edgar/data/1692415/000149315226014158/) |
| Research and development | [$19.1 million](https://www.sec.gov/Archives/edgar/data/1692415/000149315226014158/) | [$21.0 million](https://www.sec.gov/Archives/edgar/data/1692415/000149315226014158/) |
| Net income (loss) | [-$46.9 million](https://www.sec.gov/Archives/edgar/data/1692415/000149315226014158/) | [-$37.6 million](https://www.sec.gov/Archives/edgar/data/1692415/000149315226014158/) |
| Cash from operations | [-$29.1 million](https://www.sec.gov/Archives/edgar/data/1692415/000149315226014158/) | [-$29.2 million](https://www.sec.gov/Archives/edgar/data/1692415/000149315226014158/) |
| Cash and equivalents | [$11.9 million](https://www.sec.gov/Archives/edgar/data/1692415/000149315226037762/) | [$2.9 million](https://www.sec.gov/Archives/edgar/data/1692415/000149315226014158/) |
| Short-term investments |  | [$26.8 million](https://www.sec.gov/Archives/edgar/data/1692415/000149315226014158/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $3.6 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Co-Diagnostics

Has Co-Diagnostics sold convertible notes?

Our latest story on this, dated Oct 9, 2026: "Co-Diagnostics issues senior secured convertible note to J.J. Astor". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/co-diagnostics-issues-senior-secured-convertible-note-j-j-astor/).

What is the ticker symbol of Co-Diagnostics?

Co-Diagnostics, Inc. trades under the ticker CODX on NASDAQ.

Where is Co-Diagnostics listed?

Co-Diagnostics, Inc. is listed on NASDAQ.

Which country or territory is Co-Diagnostics listed under?

Our directory records Co-Diagnostics, Inc. under United States.

Does aibio.space cover Co-Diagnostics?

aibio.space lists Co-Diagnostics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

What was Co-Diagnostics's revenue last year?

$622,489 for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is Co-Diagnostics profitable?

Co-Diagnostics, Inc. reported a net loss of $46.9 million for the fiscal year ended Dec 31, 2025, and used $29.1 million of cash in operations, per its annual report to the SEC.

How much does Co-Diagnostics spend on research and development?

$19.1 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Co-Diagnostics have?

$3.6 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest Co-Diagnostics (CODX) stock news?

Our latest story on Co-Diagnostics, dated Oct 9, 2026: "Co-Diagnostics issues senior secured convertible note to J.J. Astor". The note has an original principal amount of $2,835,000, repaid in weekly installments of $94,500. The final maturity date is May 7, 2027. [Source](https://aibio.space/news/co-diagnostics-issues-senior-secured-convertible-note-j-j-astor/).

What is Co-Diagnostics's latest stock offering or financing news?

Our latest financing story, dated Jul 31, 2026: "Co-Diagnostics warrant inducement expected to raise about $2.67 million". Holders of existing warrants agreed to exercise at $1.571 per share in exchange for new warrants at $1.56. Maxim Group LLC is the exclusive placement agent. [Source](https://aibio.space/news/co-diagnostics-warrant-inducement-expected-raise-about-2-67-million/).

Who were the underwriters or placement agents on Co-Diagnostics's offering?

From our story: Co-Diagnostics, Inc., a Utah corporation, issued a senior secured convertible note to J.J. Astor & Co., the lender, with an original issue date of October 9, 2026. [Source](https://aibio.space/news/co-diagnostics-warrant-inducement-expected-raise-about-2-67-million/).

How can I follow Co-Diagnostics (CODX) news?

Press Follow on this page to add Co-Diagnostics to your Following list, or subscribe to the aibio.space newsletter. We have published 6 stories naming Co-Diagnostics so far, in Company Updates, Debt Financing, Financings.

## Investor discussion: Co-Diagnostics

Members talk about Co-Diagnostics (CODX). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Co-Diagnostics, newest first. Each line links the filing it comes from.

1. 2026-10-26 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1692415/000149315226048507/formdef14a.htm)
2. 2026-10-16 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1692415/000149315226047441/formpre14a.htm)
3. 2026-09-21 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1692415/000149315226043582/formpre14a.htm)
4. 2026-07-27 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1692415/000149315226034835/form424b5.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CODX on TradingView](https://www.tradingview.com/symbols/NASDAQ-CODX/).

## Listing details

Co-Diagnostics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CODX, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Co-Diagnostics, Inc.

- **Ticker**: CODX

- **Listing**: NASDAQ

- **Country or territory**: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/diagnostics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Co-Diagnostics (CODX) news: convertible notes", 2026-10-31, https://aibio.space/companies/diagnostics/